The Hemodynamic Response to Prolonged Dobutamine Infusion
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A decrease in the response of beta 1 adrenergic receptors to agonists (desensitization) is
thought to play a major role in the pathogenesis of diseases such as congestive heart
failure. However, currently, there is no in vivo model that will enable us to measure
desensitization of the hemodynamic responses to beta 1 adrenergic receptors in vivo.
Our hypothesis is that constant 3 hours intravenous infusion of the selective beta1
adrenergic receptor agonist dobutamine will result in gradual decline in hemodynamic
responses to dobutamine over time.